BCL2L1 and Thrombocytopenia: We have used the PROTAC technology to reduce navitoclax thrombocytopenia by converting it into a VHL E3 ligase targeted BCL-xL PROTAC, such as DT2216, because platelets are devoid of the VHL E3 ligase required for BCL-xL degradation [32].